Skip to main
CRMD

CorMedix (CRMD) Stock Forecast & Price Target

CorMedix (CRMD) Analyst Ratings

Based on 5 analyst ratings
Strong Buy
Strong Buy 60%
Buy 40%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Cormedix Inc. is poised for significant growth, particularly with its product DefenCath, which is projected to see improved pricing and increased sales following enhanced reimbursement from CMS and its expansion into total parenteral nutrition (TPN). Management’s long-term financial guidance indicates expected DefenCath sales of $100 million to $140 million by 2027, reflecting confidence in the product's market potential and the predictive nature of the TDAPA formula that anticipates a 3x-5x improvement in pricing. Additionally, the successful integration of the Momenta acquisition, which contributed approximately $140 million in pro forma revenue and generated operational synergies exceeding $35 million within mere months, further solidifies Cormedix's operational foundation and indicates a strong trajectory for future growth.

Bears say

Cormedix Inc. has issued revenue guidance for 2026 and 2027 that falls significantly short of analyst expectations, leading to a negative outlook for the company. The guidance indicates a top-line revenue of $300 million to $320 million, which is a decrease from the previous projections of approximately $400 million for 2025, primarily driven by anticipated declines in DefenCath sales due to competitive pressures and revenue cliffs after mid-2026. Additionally, there are concerns regarding the potential for high discontinuation rates associated with DefenCath and competition from generics, which may further impact sales and market penetration.

CorMedix (CRMD) has been analyzed by 5 analysts, with a consensus rating of Strong Buy. 60% of analysts recommend a Strong Buy, 40% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of CorMedix and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About CorMedix (CRMD) Forecast

Analysts have given CorMedix (CRMD) a Strong Buy based on their latest research and market trends.

According to 5 analysts, CorMedix (CRMD) has a Strong Buy consensus rating as of Apr 6, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $15.20, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $15.20, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

CorMedix (CRMD)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.